Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

cisplatin micelle formulation HA132

A micelle formulation containing the inorganic platinum agent cisplatin, with potential antineoplastic activity. Upon administration, cisplatin forms highly reactive, charged, platinum complexes which bind to nucleophilic groups such as GC-rich sites in DNA inducing intrastrand and interstrand DNA cross-links, as well as DNA-protein cross-links. These cross-links result in apoptosis and growth inhibition of tumor cells.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	cisplatin micelle HA132
Code name:	HA 132 HA-132 HA132

cisplatin micelle formulation HA132

Search NCI's Drug Dictionary